References
- Lelo A, Miners J O, Robson R A, Birkett D J. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 1986; 22: 183–6
- Fuhr U, Doehmer J, Battula N, Wölfel C, Kudla C, Keita Y, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered from expression of single cytochrome P450 isoforms. Biochem Pharmacol 1992; 43: 225–35
- Gu L, Gonzalez F J, Kalow W, Tang B K. Biotransfonnation of caffeine, paraxanthine, theo-bromine and theophylline by CDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73–7
- Tassaneeyakul W, Birkett D J, McManus M E, Tassaneeyakul W, Veronese M E, Anderson T, et al. Caffeine metabolism by human hepatic cytochromes P450 contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767–76
- Rodopoulos N, Wisén O, Norman A. caffeine metabolism in patients with liver disease. Scand J Clin Lab Invest 1995; 55: 229–42
- Taka S M, Arnaud M J, Dvorcbik B H, Vesell E S. Theobromine kinetics and metabolic disposition. Clin Pharmacol Ther 1983; 34: 546–55
- Shivcly C A, Tarka S M, Arnaud M J, Dvorchik B H, Passananti G T, Vesell E S. Higb levels of methyl-xanthines in chocolate do not alter theobromine disposition. Clin Pharmacol Ther 1985; 37: 415–24
- Birkett D J, Dahlqvist R, Miners J O, Lelo A, Billing B. Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos 1985; 13: 725–8
- Miners J O, Attwood J, Birkett D J. Theobromine metabolism in man. Drug Metab Dispos 1982; 10: 672–5
- Miners J O, Wing L MH, Attwood J. Theobromine metabolism in man: effects of cimetidine and sulph-inpyrazone. Clin Exp Phamacol Physiol 1983; 10: 688
- Thormann W, Minger A, Molteni S, Caslavska J, Gebauer P. Determination of substituted purines in body fluids by micellar electrokinetic capillary chromatography with direct sample injection. J Chromatogr 1992; 593: 275–88
- Rodopoulos N, Norman A. Determination of caffeine and its metabolites in urine by high-perfonnance liquid chromatography and capillary electrophoresis. Scand J Clin Lab Invest 1994; 54: 305–15
- Rodopoulos N, Norman A. Assessment of dimethylxanthine formation from caffeine in healthy adults: comparison between plasma and saliva concentrations and urinary excretion of metabolites. Scand J Clin Lab Invest 1996, In press
- Drouillard D D, Vesell E S, Dvorchik B H. Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines. Clin Phamacol Ther 1978; 23: 296–302
- Miners J O, Attwood J, Wing L MH, Birkett D J. Influence of cimetidine, sdfinpyrazone, and cigarette smoking on theobromine metabolism in man. Drug Metab Dispos 1985; 13: 598–601
- Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503–14
- Tang B-K, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYPlA2 activity: potencial influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117–24
- Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar F F, Kamataki. Phenotyping of CYPlA2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomark Prevent 1994; 3: 413–21
- Carrillo J A, Benitez J. Caffeine metabolism in healthy Spanish population: N-mtylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293–304
- Parks D A, Granger D N. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand 1986; 87–99, Suppl 548
- Wajner M, Harkness R A. Distribution of xanthhe dehydrogenase and oxidase activities in human and rabbit tissues. Biochim Biophys Acta 1989; 991: 79–84